| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
Purity: ≥98%
| Targets |
TGF-β receptor type I (TGF-βRI) kinase (IC50 = 56 nM)
TGF-β receptor type I (TGFβRI/ALK5). Galunisertib selectively inhibits TGFβRI kinase activity, blocking the phosphorylation of SMAD2/3 and downstream TGF-β signaling. This inhibits TGF-β-mediated effects on cell proliferation, differentiation, migration, and immune evasion. |
|---|---|
| ln Vitro |
LY2157299 (also known as Galunisertib) potently inhibits the TGFβ receptor signaling. LY2157299 abolishes the TGFβ induced Smad2 phosphorylation in HUVEC cells. LY2157299 also shows dose dependent potentiation of VEGF or bFGF induced cell proliferation in HUVEC. LY2157299 also promotes VEGF induced HUVEC cell migration. LY2157299 potentiates angiogenesis in the in vitro VEGF-stimulated cord formation assay. Y2157299 inhibits TGF-β-mediated SMAD2 activation and hematopoietic suppression in primary hematopoietic stem cells in a dose-dependent manner. LY2157199 treatment stimulates hematopoiesis from primary MDS bone marrow specimens. In human glioblastoma (GBM) cells, LY2157299 treatment blocks signaling through the heteromeric TGFβ receptor complex to reduce levels of active, phosphorylated SMAD.
Kinase Assay: LY2157299 (also known as Galunisertib) is a potent, selective ATP-mimetic inhibitor of TGF-β receptor (TβR)-I activation LY2157299 (0.1, 1, 10, and 100 μM) displays a slight dose-dependent potentiation of Sorafenib in SK-Sora, HepG2, and Hep3B cell lines but not in JHH6, SK-HEP1, and HuH7 cell lines. Cell Assay: Cell survival is determined using the MTT assay. The conversion of yellow water-soluble tetrazolium MTT into purple insoluble formazan is catalyzed by mitochondrial dehydrogenases and used to estimate the number of viable cells. In brief, cells are seeded in 96-well tissue culture plates at a density of 2×103 cells/well. After drug exposure, cells are incubated with 0.4 mg/mL MTT for 4 hours at 37°C. After incubation, the supernatant is discarded, insoluble formazan precipitates are dissolved in 0.1 mL of DMSO, and the absorbance is measured at 560 nm by use of a microplate reader. Wells with untreated cells or with drug-containing medium without cells are used as positive and negative controls respectively. For proliferation assay, MTT assay is done daily to determine the number of viable cells in untreated control and LY2157299 (0.1, 1, 10, and 10 μM)-treated group. Galunisertib is a potent and selective TGFβRI inhibitor. Its activity is assessed using recombinant TGFβRI kinase and a fluorescent peptide substrate. It inhibits SMAD2 phosphorylation in cells with an IC50 in the nanomolar range. |
| ln Vivo |
Although anti-tumor activity has been observed in several pre-clinical models, LY2157299 fails to show significant in vivo angiogenic effects in the 4T1, Colo205, or A549 xenograft models. Administration of LY2157299 ameliorates anemia in a TGF-β overexpressing transgenic mouse model of bone marrow failure. Oral administration of LY2157299 at 75 mg/kg/day displays significant antitumor activity against both Calu6 and MX1 xenografts in mice. In vivo, LY2157299 induces angiogenesis and enhances VEGF and basic-fibroblast-growth-factor-induced angiogenesis in a Matrigel-plug assay, whereas adding an alpha5-integrin-neutralizing antibody to the Matrigel selectively inhibits this enhanced response.
In vivo, galunisertib is orally active and demonstrates antitumor activity in preclinical models. It has been evaluated in clinical trials for various cancers, including hepatocellular carcinoma and glioblastoma. |
| Enzyme Assay |
Recently, kinase inhibitors have shown great potential against fibrotic diseases and, specifically, the transforming growth factor-β receptor (TGF-βR) was found as a new and promising target for scleroderma therapy. In the current study, we propose that the large pool of existing kinase inhibitors could be exploited for inhibiting the TGF-βR to suppress scleroderma. In this respect, we developed a modeling protocol to systematically profile the inhibitory activities of 169 commercially available kinase inhibitors against the TGF-βR, from which five promising candidates were selected and tested using a standard kinase assay protocol. Consequently, two molecular entities, namely the PKB inhibitor MK-2206 and the mTOR C1/C2 inhibitor AZD8055, showed high potency when bound to the TGF-βR, with IC50 values of 97 and 86 nM, respectively, which are close to those of the recently developed TGF-βR selective inhibitors SB525334 and galunisertib/LY2157299 (IC50 = 14.3 and 56 nM, respectively). We also performed atomistic molecular dynamics simulations and post-molecular mechanics/Poisson–Boltzmann surface area analyses to dissect the structural basis and energetic properties of intermolecular interactions between the TGF-βR kinase domain and these potent compounds, highlighting intensive nonbonded networks across the tightly packed interface of non-cognate TGF-βR-inhibitor complexes[Arch Pharm (Weinheim). 2014 Sep;347(9):609-15.].
TGFβRI inhibition assays use recombinant TGFβRI kinase and a fluorescent peptide substrate. Galunisertib is incubated with the enzyme and substrate, and kinase activity is measured by fluorescence polarization or mobility shift. IC50 values are determined from dose-response curves. |
| Cell Assay |
Even though myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis, the molecular alterations that lead to marrow failure have not been well elucidated. We have previously shown that the myelosuppressive TGF-β pathway is constitutively activated in MDS progenitors. Because there is conflicting data about upregulation of extracellular TGF-β levels in MDS, we wanted to determine the molecular basis of TGF-β pathway overactivation and consequent hematopoietic suppression in this disease. We observed that SMAD7, a negative regulator of TGF-β receptor I (TBRI) kinase, is markedly decreased in a large meta-analysis of gene expression studies from MDS marrow-derived CD34(+) cells. SMAD7 protein was also found to be significantly decreased in MDS marrow progenitors when examined immunohistochemically in a bone marrow tissue microarray. Reduced expression of SMAD7 in hematopoietic cells led to increased TGF-β-mediated gene transcription and enhanced sensitivity to TGF-β-mediated suppressive effects. The increased TGF-β signaling due to SMAD7 reduction could be effectively inhibited by a novel clinically relevant TBRI (ALK5 kinase) inhibitor, LY-2157299. LY-2157299 could inhibit TGF-β-mediated SMAD2 activation and hematopoietic suppression in primary hematopoietic stem cells. [1]
In vitro cell assays for galunisertib include measuring SMAD2 phosphorylation by Western blotting in TGF-β-stimulated cells. Cell proliferation is assessed by MTT or CTG assays. Epithelial-mesenchymal transition is assessed by measuring E-cadherin and vimentin expression. |
| Animal Protocol |
Dissolved in DMSO and diluted in saline; 75 mg/kg/day; oral gavageNude mice implanted subcutaneously with Calu6 or MX1 cells
In vivo animal protocols for galunisertib use mouse xenograft models of cancer (e.g., hepatocellular carcinoma, pancreatic cancer). The compound is administered orally. Tumor growth inhibition is measured. |
| References |
[1]. Cancer Res.2011 Feb 1;71(3):955-63.
|
| Additional Infomation |
LY-2157299 is a pyrrolopyrazole compound with the structure 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole, where the 2 and 3 positions are substituted with 6-methylpyridin-2-yl and 6-(aminocarbonyl)quinoline-4-yl, respectively. It is a transforming growth factor-βRI (TGF-βRI) kinase inhibitor that blocks TGF-β-mediated tumor growth in glioblastoma. It has a dual role as a TGF-β receptor antagonist and an antitumor drug. LY-2157299 belongs to the quinoline, pyrrolopyrazole, methylpyridine, aromatic amide, and monocarboxylic acid amide classes. Galunisertib has been used in basic science research and clinical trials for the treatment of various diseases, including glioma, tumors, solid tumors, glioblastoma, and prostate cancer. Furthermore, in vivo administration of LY-2157299 improved anemia in a TGF-β overexpressing transgenic mouse model of bone marrow failure. More importantly, LY-2157299 treatment can stimulate hematopoietic function in bone marrow specimens of primary MDS. These studies show that the reduction of SMAD7 is a novel molecular alteration in MDS, which leads to ineffective hematopoiesis by activating the TGF-β signaling pathway in hematopoietic cells. These studies also elucidate the potential application value of TBRI inhibitors in the treatment of MDS. [1]
|
| Molecular Formula |
C22H21N5O2
|
|---|---|
| Molecular Weight |
387.434444189072
|
| Exact Mass |
387.17
|
| CAS # |
924898-09-9
|
| Related CAS # |
700874-72-2;924898-09-9 (hydrate);
|
| PubChem CID |
15945857
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
4.333
|
| tPSA |
96.91
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
29
|
| Complexity |
585
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(C1=CC=C2N=CC=C(C3=C(CCC4)N4N=C3C5=NC(C)=CC=C5)C2=C1)N.O
|
| InChi Key |
UZOSBNQFZUJWFP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H19N5O.H2O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)1H2
|
| Chemical Name |
4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide hydrate
|
| Synonyms |
Galunisertib Monohydrate; LY2157299 monohydrate; LY-2157299 monohydrate; galunisertib monohydrate; 924898-09-9; Galunisertib (hydrate); Galunisertib (monohydrate); 924898-09-9 (hydrate); 338K210Q5W; 4-[2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide hydrate; 4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide;hydrate; LY 2157299 monohydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5811 mL | 12.9056 mL | 25.8111 mL | |
| 5 mM | 0.5162 mL | 2.5811 mL | 5.1622 mL | |
| 10 mM | 0.2581 mL | 1.2906 mL | 2.5811 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|---|
|
|